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Background
Renal Denervation (RDN) is a novel therapy for patients
with resistant hypertension. Its cardiac effects at follow-
up are currently unknown. On the other hand, T1 map-
ping permits the assessment of myocardial extracellular
volume (ECV), a parameter proposed to quantify diffuse
myocardial fibrosis and independently associated with
mortality and hard cardiovascular events. Our aim was to
study the effects of RDN on ECV at 6-month follow-up.
Methods
14 patients with resistant hypertension undergoing RD
(RD group) and 4 resistant hypertensive patients not
undergoing RD (control group) were prospectively
included. A 1.5T cardiac MR including T1 mapping pre-
and post-contrast was performed before the RD procedure
and at 6-month follow-up in both groups. Blood hemato-
crit was determined at both time points. Images were
post-processed using commercial software (Qmass, Medis
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Figure 1 Percent ECV-change baseline versus 6-months follow-up in patients with resistant hypertenstion undergoing renal
denervation and hypertensive controls.
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Medical Solutions, the Netherlands), and whole left ventri-
cle (LV) ECV and septal ECV at baseline and at 6-month
follow-up were quantified as follows: ECV = (1-hemato-
crit) * l, where l = (1/T1 myocardium post-contrast - 1/
T1 myocardium pre-contrast)/(1/T1 blood post-contrast -
1/T1 blood pre-contrast).
Results
No significant differences in whole LV ECV or septal
ECV were observed between baseline and 6-month fol-
low-up in the RD group. In contrast, control patients
presented an increase in whole LV ECV and septal ECV
at 6-month follow-up which did not reach statistical sig-
nificance (p = 0.14 and p = 0.11, respectively). When
the results were expressed as a % of change versus base-
line, the % change of ECV septal was significantly differ-
ent between the RDN and control groups (-5.4 ± 14.4
(-3.8) vs 22.9 ± 4.2 (21.5), respectively, p = 0.02; results
expressed as mean ± SD (median)) (Figure 1).
Conclusions
Extracellular space could increase at follow-up in non-
RDN patients, potentially reflecting a progressive
increase in myocardial fibrosis content. This effect is not
observed in RDN patients, suggesting a beneficial effect
of RDN in delaying this fibrotic progression. Our results
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